The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

Citations Over TimeTop 21% of 2010 papers

Abstract

Exacerbations contribute significantly to the morbidity of COPD, leading to an accelerated decline in lung function, reduced functional status, reduced health status and quality of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an important goal of COPD management. In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 microg) and the long-acting beta(2)-agonist salmeterol (50 microg) in a single inhaler (250/50 microg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. Importantly, results of various studies suggest that fluticasone propionate and salmeterol have synergistic effects when administered together that improve their efficacy in controlling symptoms and reducing exacerbations. The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs.

Related Papers

• → Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone(2016)155 cited
• → Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma(1999)99 cited
• → Inhaled Salmeterol/Fluticasone Propionate(2005)31 cited
• → Improvements in asthma outcomes following 1 year of treatment with salmeterol/fluticasone or fluticasone alone when stepped up to achieve guideline-defined total control(2004)6 cited